Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Jemal, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries., CA Cancer J Clin, 6, 394, 10.3322/caac.21492
Reznik, 2021, The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management., Eur Urol, 7, 468, 10.1016/j.eururo.2020.09.027
Merseburger, 2016, European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy., Eur Urol, 7, 705, 10.1016/j.eururo.2016.06.009
Griffioen, 2021, Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes., Nat Rev Clin Oncol, 1, 527, 10.1038/s41571-021-00496-y
Tawbi, 2021, Development of Immunotherapy Combination Strategies in Cancer., Cancer Discov, 1, 1368, 10.1158/2159-8290.CD-20-1209
Grivas, 2021, Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial., Lancet Oncol, 2, 525, 10.1016/S1470-2045(21)00004-8
Parnis, 2021, Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial., Eur Urol, 7, 659, 10.1016/j.eururo.2020.06.021
Alekseev, 2019, Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial., Lancet, 39, 2404, 10.1016/S0140-6736(19)30723-8
Steinharter, 2021, Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma., Cancer Cell, 3, 649, 10.1016/j.ccell.2021.02.015
Forman, 2021, Progressive immune dysfunction with advancing disease stage in renal cell carcinoma., Cancer Cell, 3, 632, 10.1016/j.ccell.2021.02.013
McDermott, 2015, Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma., Cancer Immunol Res, 3, 1158, 10.1158/2326-6066.CIR-15-0043
Chen, 2021, Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma., Cancers (Basel), 1, 1475, 10.3390/cancers13061475
Finke, 2020, The immunology of renal cell carcinoma., Nat Rev Nephrol, 1, 721, 10.1038/s41581-020-0316-3
Seung, 1999, Learning the parts of objects by non-negative matrix factorization., Nature, 40, 788, 10.1038/44565
Canzar, 2021, A generalization of t-SNE and UMAP to single-cell multimodal omics., Genome Biol, 2, 130, 10.1186/s13059-021-02356-5
Mesirov, 2004, Metagenes and molecular pattern discovery using matrix factorization., Proc Natl Acad Sci USA, 10, 4164, 10.1073/pnas.0308531101
Mesirov, 2007, Metagene projection for cross-platform, cross-species characterization of global transcriptional states., Proc Natl Acad Sci USA, 10, 5959, 10.1073/pnas.0701068104
Han, 2008, Non-negative Matrix Factorization on Manifold., 2008 Eighth IEEE International Conference on Data Mining, 63, 10.1109/ICDM.2008.57
Valencia, 2021, Multi-project and Multi-profile joint Non-negative Matrix Factorization for cancer omic datasets., Bioinformatics, 10.1093/bioinformatics/btab579
Luo, 2020, Integrative genomic study of Chinese clear cell renal cell carcinoma reveals features associated with thrombus., Nat Commun, 1, 739, 10.1038/s41467-020-14601-9
Larose, 2018, Epidemiology and Risk Factors for Kidney Cancer., J Clin Oncol, 3, JCO2018791905, 10.1200/JCO.2018.79.1905
Hong, 2017, Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma., JCI Insight, 2, e93411, 10.1172/jci.insight.93411
Damotte, 2015, Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer., Clin Cancer Res, 2, 3031, 10.1158/1078-0432.CCR-14-2926
Coukos, 2011, Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin., Curr Top Microbiol Immunol, 34, 129, 10.1007/82_2010_95
Galon, 2012, The immune contexture in human tumours: impact on clinical outcome., Nat Rev Cancer, 1, 298, 10.1038/nrc3245
Savas, 2017, Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis., Lancet Oncol, 1, 1009, 10.1016/S1470-2045(17)30516-8
Huang, 2021, Characterization of Hypoxia-Related Molecular Subtypes in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy and Targeted Therapy via Multi-Omics Analysis., Front Mol Biosci, 8, 684050, 10.3389/fmolb.2021.684050
Song, 2022, Pyroptosis Regulators and Tumor Microenvironment Infiltration Characterization in Clear Cell Renal Cell Carcinoma., Front Oncol, 1, 774279, 10.3389/fonc.2021.774279
Song, 2022, Adipogenic Transdifferentiation and Regulatory Factors Promote the Progression and the Immunotherapy Response of Renal Cell Carcinoma: Insights From Integrative Analysis., Front Oncol, 1, 781932, 10.3389/fonc.2022.781932
Dai, 2017, Tumor microenvironment and therapeutic response., Cancer Lett, 38, 61, 10.1016/j.canlet.2016.01.043
Mellman, 2017, Elements of cancer immunity and the cancer-immune set point., Nature, 54, 321, 10.1038/nature21349
Elkord, 2018, Immune checkpoint inhibitors: recent progress and potential biomarkers., Exp Mol Med, 5, 1, 10.1038/s12276-018-0191-1
Chen, 2019, Immune Checkpoint Inhibitors: Basics and Challenges., Curr Med Chem, 2, 3009, 10.2174/0929867324666170804143706
Xu, 2020, Immune checkpoint signaling and cancer immunotherapy., Cell Res, 3, 660, 10.1038/s41422-020-0343-4
Najafi, 2019, PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy., J Cell Physiol, 23, 1313, 10.1002/jcp.27172
Leibovich, 2017, Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection., Eur Urol, 7, 300, 10.1016/j.eururo.2016.12.027
Thompson, 2017, Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients., Eur Urol, 7, 665, 10.1016/j.eururo.2016.05.034
Tirosh, 2021, Decoupling epithelial-mesenchymal transitions from stromal profiles by integrative expression analysis., Nat Commun, 1, 2592, 10.1038/s41467-021-22800-1
Yim, 2021, PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma., Cell Death Differ, 2, 2745, 10.1038/s41418-021-00781-4
Martí, 2021, Cell intercalation driven by SMAD3 underlies secondary neural tube formation., Dev Cell, 5, 1147, 10.1016/j.devcel.2021.03.023
Eilers, 2020, Target gene-independent functions of MYC oncoproteins., Nat Rev Mol Cell Biol, 2, 255, 10.1038/s41580-020-0215-2
Li, 2018, PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis., Cell Death Dis, 9, 307, 10.1038/s41419-018-0348-9
Cui, 2020, Identification of RNA Transcript Makers Associated With Prognosis of Kidney Renal Clear Cell Carcinoma by a Competing Endogenous RNA Network Analysis., Front Genet, 1, 540094, 10.3389/fgene.2020.540094
Li, 2020, Profiling of Tumor Microenvironment Components Identifies Five Stroma-Related Genes with Prognostic Implications in Colorectal Cancer., Cancer Biother Radiopharm, 10.1089/cbr.2020.4118
Wang, 2020, Identification of a prognostic gene signature based on an immunogenomic landscape analysis of bladder cancer., J Cell Mol Med, 2, 13370, 10.1111/jcmm.15960
Carvalho, 2019, Tumor Transcriptome Reveals High Expression of IL-8 in Non-Small Cell Lung Cancer Patients with Low Pectoralis Muscle Area and Reduced Survival., Cancers (Basel), 1, 1251, 10.3390/cancers11091251